66 results
S-1/A
BOLD
Boundless Bio Inc.
21 Mar 24
IPO registration (amended)
6:04am
The following table summarizes our results of operations for each of the periods indicated:
Year Ended December 31, | ||||||||||||
(in thousands) | 2022 | 2023 | Change | |||||||||
Operating expenses: | ||||||||||||
Research and development | $ | 37,159 | $ | 42,637 | $ | 5,478 | ||||||
General and administrative | 9,310 | 12,159 | 2,849 | |||||||||
Total operating expenses | 46,469 | 54,796 | 8,327 | |||||||||
Loss from operations | (46,469) | (54,796) | (8,327) | |||||||||
Other income (expense), net | 568 | 5,362 | 4,794 | |||||||||
Net loss | $ | (45,901) | $ | (49,434) | $ | (3,533) | ||||||
S-1/A
BOLD
Boundless Bio Inc.
21 Mar 24
IPO registration (amended)
6:04am
The following table summarizes our cash flows for each of the periods indicated:
Year Ended December 31, | ||||||||||||
(in thousands) | 2022 | 2023 | Change | |||||||||
Net cash used in operating activities | $ | (39,596) | $ | (46,855) | $ | (7,259) | ||||||
Net cash provided by investing activities | 16,132 | (38,260) | (54,392) | |||||||||
Net cash provided by financing activities | 126 | 97,897 | 97,770 | |||||||||
Increase (decrease) in cash, cash equivalents, and restricted cash | $ | (23,338) | $ | 12,782 | $ | 36,119 | ||||||
S-1/A
BOLD
Boundless Bio Inc.
21 Mar 24
IPO registration (amended)
6:04am
(in thousands)
Year Ended December 31, | ||||||||
2022 | 2023 | |||||||
Cash flows from operating activities | ||||||||
Net loss | $ | (45,901) | $ | (49,434) | ||||
Reconciliation of net loss to net cash used in operating activities: | ||||||||
Stock-based compensation | 2,290 | 3,336 | ||||||
Depreciation | 942 | 957 | ||||||
Amortization (accretion) of investments, net | 503 | (3,300) | ||||||
Non-cash lease expense | 1,607 | 2,360 | ||||||
Other | 97 | 25 | ||||||
Changes in operating assets and liabilities: | ||||||||
Prepaid expenses and other assets | 217 | 85 | ||||||
Accounts payable and accrued liabilities | 1,911 | 1,663 | ||||||
Operating lease liabilities | (1,262) | (2,547) | ||||||
Net cash used in operating activities | (39,596) | (46,855) | ||||||
Cash flows from investing activities | ||||||||
Purchases of investments | (42,598) | (160,123) | ||||||
Maturities of investments | 59,796 | 122,496 | ||||||
Purchases of property and equipment | (1,066) | (633) | ||||||
Net cash provided by (used in) investing activities | 16,132 | (38,260) | ||||||
Cash flows from financing activities | ||||||||
Proceeds from issuance of Series C preferred stock, net of issuance costs | — | 99,671 | ||||||
Payment of deferred offering costs | — | (1,956) | ||||||
Proceeds from the exercise of stock options | 126 | 182 | ||||||
Net cash provided by financing activities | 126 | 97,897 | ||||||
Net increase (decrease) in cash and cash equivalents | (23,338) | 12,782 | ||||||
Cash, cash equivalents, and restricted cash at beginning of year | 34,822 | 11,484 | ||||||
Cash, cash equivalents, and restricted cash at end of year | $ | 11,484 | $ | 24,266 | ||||
Components of cash, cash equivalents, and restricted cash | ||||||||
Cash and cash equivalents | $ | 10,951 | $ | 23,706 | ||||
Restricted cash | 533 | 560 | ||||||
Cash, cash equivalents, and restricted cash at end of year | $ | 11,484 | $ | 24,266 | ||||
Non-cash investing and financing activities | ||||||||
Deferred offering costs in accounts payable and accrued expenses | $ | — | $ | 197 | ||||
Addition to ROU assets | $ | 5,506 | $ | 282 | ||||
Increase (decrease) to ROU assets due to remeasurement of lease obligation | $ | 562 | $ | (723) | ||||
Vesting of early exercised stock options | $ | 206 | $ | 92 | ||||
Unpaid property and equipment purchases | $ | 102 | $ | — | ||||
S-1/A
BOLD
Boundless Bio Inc.
21 Mar 24
IPO registration (amended)
6:04am
December 31, 2023 | ||||||||||||||||
Acquisition Cost | Unrealized Gain | Unrealized Loss | Estimated Fair Value | |||||||||||||
Money market funds | $ | 21,737 | $ | — | $ | — | $ | 21,737 | ||||||||
U.S. government obligations | 92,106 | 58 | (21) | 92,143 | ||||||||||||
Corporate debt securities | 4,900 | 5 | (2) | 4,903 | ||||||||||||
Total available-for-sale securities | $ | 118,743 | $ | 63 | $ | (23) | $ | 118,783 | ||||||||
Classified as: | ||||||||||||||||
Cash equivalents | $ | 21,737 | ||||||||||||||
Short-term investments | 97,046 | |||||||||||||||
Total cash equivalents and investments | $ | 118,783 | ||||||||||||||
S-1/A
BOLD
Boundless Bio Inc.
21 Mar 24
IPO registration (amended)
6:04am
The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock options granted during the following periods were as follows:
Year Ended December 31, | ||||||||
2022 | 2023 | |||||||
Expected term (in years) | 6.0 | 6.0 | ||||||
Expected volatility | 94.0% | 92.4% | ||||||
Risk-free interest rate | 2.5% | 3.9% | ||||||
Expected dividend yield | 0.0% | 0.0% |
S-1/A
q29h gzyju
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
b56kpud
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
pealpfyt
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
juvgotznip 77oc
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
ha2gzfesrmilf
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
a3oy9korcn sd
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
66ukxj
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
7p0ay
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
9bcg7zwaqropdpc
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
3b8poikgh1h
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
cuhox4
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
06g9u 15ib
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
rux8h6fusz2zrqvi
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
wytk518wcgs
21 Mar 24
IPO registration (amended)
6:04am
S-1/A
kcghpux
21 Mar 24
IPO registration (amended)
6:04am